PharmaEssentia closes enrollment in Phase 3 interferon trial for early myelofibrosis

The status change

PharmaEssentia's registry record for NCT06468033 now shows the trial as Active, not recruiting, with enrollment finalized at 160 patients, up from a prior count of 150. The primary completion date moved from September 30, 2027 to November 18, 2027 in the same update. The trial is a randomized, double-blind, placebo-controlled study of ropeginterferon alfa-2b, marketed as BESREMI, in adults with pre-fibrotic or early primary myelofibrosis, or overt disease at low or intermediate-1 risk by the DIPSS Plus scoring system. NCT06468033P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 RiskNCT06468033

Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.

Endpoint Met89%

Completes98%

Clinical Significance20%

Regulatory91%

What the trial tests

The primary endpoint is a composite measure the study calls clinically relevant complete hematologic response, tracked at 80 weeks: absence of major thrombotic events, hemoglobin at or above 10.0 g/dL, platelet count at or below 400 x 10^9/L, white blood cell count at or below 10 x 10^9/L, no progression on the symptom burden score, and no progression to secondary acute myeloid leukemia. Patients eligible for JAK inhibitor therapy at screening are excluded, positioning the drug for a segment of the population not yet candidates for the more advanced standard treatment. NCT06468033P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 RiskNCT06468033

Operational read

Enrollment landed exactly at its 160-patient target with no cut, an outcome the operational model reads as a typical, non-alarming change. The primary completion date has shifted three times since the trial was first submitted in mid-2024, moving from June 2026 to March 2027, then September 2027, then to its current November 2027 mark, a cumulative delay of roughly 535 days from the original date. The status move to Active, not recruiting follows directly from enrollment closing on schedule, a routine sequence for a trial at this stage. NCT06468033P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 RiskNCT06468033

Competitive position

Ropeginterferon alfa-2b already holds FDA approval as BESREMI for a related myeloproliferative disease, though not for primary myelofibrosis, where this trial is investigational. Within primary myelofibrosis, this is the only Phase 3 trial targeting IFNAR1, ahead of a Phase 2 program from Genrix testing a different IFNAR1-targeting antibody in an unrelated indication. PharmaEssentia's own Phase 4 ropeginterferon trial in polycythemia vera is the closest same-drug comparator, sharing target and modality but running in a different blood cancer. The broader myelofibrosis field includes Phase 3 programs from Takeda, Novartis, Geron, and Merck testing distinct mechanisms, activin ligand traps, BET inhibitors, telomerase inhibitors, and LSD1 inhibitors, none of which compete on the interferon pathway this trial tests. NCT06290765

The readthrough

The trial sits in a field the underlying landscape data characterizes as challenging: the one prior industry trial pairing IFNAR1 with primary myelofibrosis terminated rather than completing, and overall research activity targeting IFNAR1 has declined to roughly 7% of its prior volume. Against that backdrop, the bar for this readout is not just a statistically favorable composite response, but a durable effect that holds up against a mechanism-target history with no completed precedent in this specific indication.

This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.